Alliancebernstein L.P. Purchases 107,916 Shares of DexCom, Inc. (NASDAQ:DXCM)

Alliancebernstein L.P. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 24.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 555,164 shares of the medical device company's stock after purchasing an additional 107,916 shares during the period. Alliancebernstein L.P. owned approximately 0.14% of DexCom worth $43,175,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Watts Gwilliam & Co. LLC purchased a new position in DexCom in the fourth quarter worth $3,334,000. Congress Asset Management Co. grew its position in DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after acquiring an additional 1,332,522 shares in the last quarter. Janney Montgomery Scott LLC grew its position in DexCom by 2,226.6% in the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after acquiring an additional 222,548 shares in the last quarter. First Hawaiian Bank grew its position in DexCom by 556.1% in the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock worth $1,801,000 after acquiring an additional 19,629 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in DexCom in the fourth quarter worth $5,812,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is owned by corporate insiders.

Remove Ads

DexCom Price Performance

Shares of DXCM traded up $2.00 during trading hours on Thursday, reaching $68.84. 3,214,936 shares of the stock traded hands, compared to its average volume of 4,147,132. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $141.25. The company's 50-day moving average price is $77.74 and its two-hundred day moving average price is $76.63. The company has a market cap of $26.99 billion, a P/E ratio of 48.66, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on DXCM. Mizuho began coverage on shares of DexCom in a research report on Thursday. They set an "outperform" rating and a $85.00 price target for the company. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.